CAMP
Camp4 Therapeutics Corp
NASDAQ · Healthcare · Biotechnology · US
$3.85
+0.52%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$4.01
From 52W high−46.00%
Volume65466.00
Market cap$241.60M
P/E (TTM)—
P/S (TTM)57.3x
Div yield—
Key dataNov 4, 2026
Open
$4.01
From 52W high
−46.00%
Volume
65466.00
Market cap
$241.60M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.2x
P/E (TTM)
—
RSI (14)
52.7
MomentumView details →
1D Return
+0.52%
YTD Return
−38.42%
SummaryUpdated Jun 1, 2026
CAMP4 Therapeutics Corporation (NASDAQ:CAMP) is a biotechnology company founded in 2015 by renowned scientists Richard A. Young and Leonard Zon, headquartered in Cambridge, Massachusetts. The company went public in October 2024 through an initial public offering. CAMP4 operates as a clinical-stage biotechnology company focused on discovering and developing novel treatment options for patients with serious diseases through its proprietary regulatory RNA platform technology.
Similar companies
Latest newsMore news →
Camp4 Therapeutics Corp received European Union approval for a clinical trial application to conduct a Phase 1/2 trial of CMP-002 in patients with SYNGAP1-related disorder.8d agoThe UK's Medicines and Healthcare products Regulatory Agency authorized CAMP4 Therapeutics to conduct a Phase 1/2 human clinical trial of CMP-002 in patients with SYNGAP1-related disorder.55d ago